Merck & Co
Merck taps Parexel to help it meet biosimilar ambitions
January 18, 2011Research and Development Merck & Co, Parexel, biosimilars
Merck & Co has enlisted the aid of contract research organisation Parexel to help it develop biosimilar versions of some …
Regulators fast-track Merck’s hepatitis C drug boceprevir
January 7, 2011Sales and Marketing Merck & Co, boceprevir, hepatitis C, telaprevir
Merck’s new oral hepatitis C drug boceprevir will receive fast track reviews from both the FDA and the EMA after …
Merck acquires innovative insulin firm SmartCells
December 3, 2010Research and Development Merck, Merck & Co, SmartCells, diabetes, insulin
Merck has bolstered its early stage diabetes portfolio with the acquisition of SmartCells, a private pharma firm that’s developing a …
New chief executive for Merck & Co
December 1, 2010Manufacturing and Production, Research and Development, Sales and Marketing Kenneth Frazier, Merck, Merck & Co, Richard Clark, Schering-Plough
Kenneth Frazier is to be the next chief executive of Merck & Co from 1 January 2011 following his election …
Merck to develop new class of antibacterials
October 6, 2010Research and Development BioRelix, Merck & Co, anti-infectives
Merck & Co has signed a drug development agreement with anti-infective pharma firm BioRelix to development a new class of …
Merck plans jobs cuts in Ireland
September 10, 2010Manufacturing and Production Ireland, Merck & Co, Schering-Plough, job cuts
A manufacturing plant in Ireland is the latest to face staff cuts in the wake of Merck & Co’s merger …
Merck averts day in court over Dutch plant closure
September 7, 2010Manufacturing and Production, Research and Development Merck & Co, Netherlands, job cuts
Merck & Co has postponed the planned closure of the former Organon facility in Oss, the Netherlands, after weeks of …
Merck wins double approval in Europe
September 3, 2010Sales and Marketing Brinavess, Merck & Co, Syncrest, merck sharp and dohme
European regulators have given the green light for two of Merck & Co’s new drugs, licensing its anti-psychotic treatment Sycrest …
Merck signs Alzheimer’s deal with Alectos
August 16, 2010Research and Development, Sales and Marketing Alzheimer's, Alzheimers, Merck & Co
Merck has entered a $289 million agreement with Canadian company Alectos Therapeutics in a bid to find new Alzheimer’s drugs. …
Pharma manufacturing news in brief
August 13, 2010Manufacturing and Production Dutch CMO SynCo Bio Partners, GeoPharma, Merck & Co, Positron, SCM Pharma, Thermo Fisher Scientifitic
EMA and FDA issue call for volunteers for joint inspection pilot, plus facility updates from Merck & Co, Thermo Fisher …
Organon workers challenge Merck on Dutch facility closure
August 3, 2010Manufacturing and Production, Research and Development Merck & Co, job cuts
Merck & Co’s decision to close down the former Organon facility in Oss, the Netherlands, looks set to be challenged …
Merck merger costs halve profits
August 2, 2010Sales and Marketing 2010 financials, Merck & Co, Q2
Shares in Merck & Co fell as costs relating to the merger with Schering-Plough put a huge dent in second …
Manufacturing news in brief
July 20, 2010Manufacturing and Production Apicore, Emergent, Merck & Co, PPS, Tianyin, lilly
A crop of facility announcements from Merck & Co, Emergent, Tianyin, Apicore and PPS offset more job loss news from …
Merck moves tropical disease drug into phase II
June 25, 2010Research and Development Chagas disease, Merck & Co, Noxafil, tropical disease
Merck & Co is to see whether its oral antifungal agent Noxafil (posaconazole) can be used in chronic cases of …
Merck’s Brinavess performs in phase III
May 18, 2010Research and Development Brinavess, Merck & Co, atrial fibrilation
Merck & Co’s heart disorder drug Brinavess has proved superior to rival amiodarone in reducing rates of atrial fibrillation in …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
